Prognostic value of EPCR-PAR1 anti-inflammatory pathway in kidney renal clear-cell carcinoma

CHANG Dichao; LIU Xuanqi; ZHU Lingyan; BAI Li

doi:10.16833/j.cnki.jbmc.2025.01.011

Journal of Baotou Medical College >

2025 , Vol. 41 >Issue 1: 60 - 67

DOI: https://doi.org/10.16833/j.cnki.jbmc.2025.01.011

Prognostic value of EPCR-PAR1 anti-inflammatory pathway in kidney renal clear-cell carcinoma

CHANG Dichao ,
LIU Xuanqi ,
ZHU Lingyan ,
BAI Li

Expand

1. Department of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Baotou 014010, China;
2. The Central Laboratory of the First Affiliated Hospieal of Baotou Medical College (Inner Mongolia Key Laboratory of Autoimmunology)

Received date: 2024-02-10

Online published: 2025-02-24

Fold

Abstract

Objective: In this study, we analyzed the relationship between the EPCR-PAR1 anti-inflammatory pathway and Kidney renal clear-cell carcinoma (KIRC), conducted an in-depth and comprehensive biological analysis, and explored new therapeutic targets in KIRC. Methods: We systematically analyzed expression of eight anti-inflammatory genes of the EPCR-PAR1 pathway in KIRC and normal samples from The Cancer Genome Atlas (TCGA) KIRC database. Using least absolute shrinkage and selection operator LASSO cox regression analysis to get a prognostic signature based on EPCR-PAR1 pathway expression. Results: We created a five-gene risk score model (risk score=0.100 82×F3+0.046 40×PROC－0.353 21×vWF+0.152 82×CAV1+0.180 69×GRK5). The prediction ability of the model was analyzed by the time-dependent ROC curve, and the prognosis model constructed by combining risk score and clinical factors had good prediction performance. Univariate and multivariate Cox regression analyses of relevant clinicopathological characters and risk score revealed that risk score was an independent risk factor for KIRC [hazard ratio (HR), 3.2; 95% confidence interval(CI), 1.9-5.6; P＜0.000 1]. Conclusion: Genes in the EPCR-PAR1 anti-inflammatory pathway could serve as auxiliary markers in the diagnosis and prognosis of KIRC.

Key words： EPCR-PAR1 anti-inflammatory pathway; KIRC; Risk score model

Cite this article

CHANG Dichao , LIU Xuanqi , ZHU Lingyan , BAI Li . Prognostic value of EPCR-PAR1 anti-inflammatory pathway in kidney renal clear-cell carcinoma[J]. Journal of Baotou Medical College, 2025 , 41(1) : 60 -67 . DOI: 10.16833/j.cnki.jbmc.2025.01.011

References

[1] Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol, 2015, 67(5): 913-924.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Cui H, Shan H, Miao MZ, et al. Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma[J]. Sci Rep, 2020, 10(1): 4271.
[4] Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma[J]. Clin Lab Med, 2005, 25(2): 433-464.
[5] Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. J Clin Oncol, 2009, 27(2): 235-241.
[6] Schutz FA, Xie W, Donskov F, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium[J]. Euro Urol, 2014, 65(4): 723-730.
[7] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[8] Bryant T. Remarks on some cases of inflammation of the breast simulating cancer[J]. Br Med J, 1868, 2(415): 608-609.
[9] Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development[J]. Sem Immunopathol, 2009, 31(2): 249-256.
[10] Murata M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23(1): 50.
[11] Kondreddy V, Wang J, Keshava S, et al. Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1[J]. Blood, 2018, 131(21): 2379-2392.
[12] Mitsui S, Oe Y, Sekimoto A, et al. Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(5): F1067-1073.
[13] Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor[J]. Blood, 2014, 124(10): 1553-1562.
[14] Pendurthi UR, Rao LVM. Endothelial cell protein C receptor-dependent signaling[J]. Curr Opin Hematol, 2018, 25(3): 219-226.
[15] Pang L, Li JF, Su L, et al. ALEX1,a novel tumor suppressor gene,inhibits gastric cancer metastasis via the PAR-1/Rho GTPase signaling pathway[J]. J Gastroenterol, 2018, 53(1): 71-83.
[16] Han N, Li H, Wang H. MicroRNA-203 inhibits epithelial-mesenchymal transition, migration, and invasion of renal cell carcinoma cells via the inactivation of the PI3K/AKT signaling pathway by inhibiting CAV1[J]. Cell Adh Migr, 2020, 14(1): 227-241.
[17] Zhao TL, Gan XX, Bao Y, et al. GRK5 promotes tumor progression in renal cell carcinoma[J]. Neoplasma, 2019, 66(2): 261-70.
[18] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-102.
[19] Cao D, Qu Y, Zhang X, et al. High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma[J]. J Cancer, 2018, 9(18): 3400-3406.
[20] Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project[J]. Nature Genetics, 2013, 45(10): 1113-1120.
[21] Goldman M, Craft B,Swatloski T,et al.The UCSC cancer genomics browser: update 2015[J]. Nucleic Acids Res, 2015, 43(Database issue): 812-817.
[22] Uhlén M, Fagerberg L,Hallström BM, et al. Proteomics tissue-based map of the human proteome[J]. Science (New York, NY), 2015, 347(6220): 1260419.
[23] Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: memorial sloan kettering cancer center 1989 to 2012 experience[J]. J Urol, 2015, 193(6): 1911-1916.
[24] Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras[J]. Cancer Med, 2016, 5(2): 169-181.
[25] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin 2017, 67(2): 93-99.
[26] Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[27] Kim SP, Alt AL, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort[J]. J Urol, 2011, 185(6): 2035-2039.
[28] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[29] Baco E, Rud E, Eri LM, et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy[J]. Eur Urol, 2016, 69(1): 149-156.
[30] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-613.

Options

Outlines

模态框（Modal）标题

Abstract

Cite this article

References